<DOC>
	<DOCNO>NCT00002982</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well give combination chemotherapy together peripheral stem cell transplantation work treat old patient refractory relapse intermediate-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Older Patients With Refractory Relapsed Intermediate-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess efficacy toxic effect carmustine/etoposide/melphalan ( ICE ) chemotherapy follow peripheral blood progenitor cell transplantation patient refractory relapse intermediate grade non-Hodgkin 's lymphoma . - Assess ability ICE chemotherapy regimen , conjunction filgrastim , mobilize peripheral blood stem cell . OUTLINE : This descriptive pilot study . Patients receive 3 cycle induction chemotherapy ifosfamide , carboplatin , etoposide ( ICE ) . Each cycle give least 14 day apart . Patients receive etoposide IV day 1 3 . Carboplatin ifosfamide mercaptoethane sulfonate give IV 24 hour day 2 . During cycle 1 2 , patient receive filgrastim ( G-CSF ) SC every 6 hour begin day 1 continue desire absolute neutrophil count ( ANC ) attain . Patients receive least 24 hour rest PBPC infusion day 0 . Following cycle 3 , G-CSF give SC begin day 6 continue completion PBPC collection . However , bone marrow harvest insufficient number stem cell collect 5 leukaphereses . Patients residual disease limit 2 site receive radiation therapy twice day within 2 week prior high dose BEAM chemotherapy carmustine , etoposide , cytarabine , melphalan . Patients receive carmustine IV day -7 . Etoposide cytarabine give IV every 12 hour day -6 -3 . Melphalan give IV day -2 . G-CSF administer every 12 hour begin day 1 continue desire ANC attain . If ANC attenuate day 21 , patient undergo repeat bone marrow biopsy receive filgrastim SC . Patients follow 2 year posttransplant , 3 5 year 4 month interval every 6 month follow fifth posttransplant . PROJECTED ACCRUAL : This study accrue 30 patient duration 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Primary refractory intermediate grade nonHodgkin 's lymphoma ( NHL ) OR Untreated relapse intermediate grade NHL 1 extranodal site disease Biopsy proven relapse diffuse large cell , diffuse mixed cell , diffuse small cleave cell ( exclude mantle cell lymphoma ) , follicular large cell , anaplastic large cell immunoblastic NHL recently attain complete response patient PATIENT CHARACTERISTICS : Age : 60 Performance status : Karnofsky least 80 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL unless history Gilbert 's disease Renal : No history chronic renal insufficiency Creatinine great 1.5 mg/dL great 1.5 mg/dL , creatinine clearance must least 60 mL/min Cardiovascular : No myocardial infarction within past 6 month No unstable angina cardiac arrhythmia chronic atrial fibrillation Normal cardiac function require ; MUGA scan stress ECG ejection fraction least 50 % without significant wall motion abnormality Pulmonary : Adequate pulmonary function define DLCO least 50 % predict value correct patient hemoglobin alveolar ventilation Other : No medical illness unrelated intermediate grade NonHodgkin 's Lymphoma No uncontrolled infection No history malignancy curatively treat cutaneous basal cell carcinoma ; carcinoma situ cervix ; axillary node negative breast cancer without prior chemotherapy disease free 2 year ; prostate cancer surgery alone disease free 2 year No lymphoblastic lymphoma , small noncleaved cell lymphoma , CNS lymphoma CNS relapse lymphoma Not HIV , HBV , HCV positive PRIOR CONCURRENT THERAPY : Concurrent enrollment MSKCC protocol 9617a allow Biologic therapy : Not specify Chemotherapy : No 2 prior chemotherapy regimen Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>